Section Arrow
Quote
JAZZ.NASDAQ
- Jazz Pharmaceuticals plc
Quotes are at least 15-min delayed:2026/02/23 19:03 EST
After Hours
Last
 173.5
+0.25 (+0.14%)
Bid
145
Ask
173.5
High 173.5 
Low 173.25 
Volume 53.31K 
Regular Hours (Closed)
Last
 173.25
+1.06 (+0.62%)
Day High 
174 
Prev. Close
172.19 
1-M High
172.46 
Volume 
1.26M 
Bid
145
Ask
173.5
Day Low
169.3571 
Open
169.84 
1-M Low
161.38 
Market Cap 
10.46B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 167.35 
20-SMA 166.66 
50-SMA 167.45 
52-W High 182.99 
52-W Low 95.49 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.16/16.78
Enterprise Value
16.58B
Balance Sheet
Book Value Per Share
65.15
Cash Flow
Cash Flow Yield
0.13
Income Statement
Total Revenue
4.07B
Operating Revenue Per Share
62.44
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.42055-1.70945-80.26%-- 
After Hours 0.4051 -0.01545 -3.67%
IBRXImmunityBio9.82+1.12+12.87%-- 
After Hours 9.82 0 0.00%
VNDAVanda Pharmaceuticals8.17+2.41+41.84%-- 
After Hours 8.32 +0.15 +1.84%
IKTInhibikase Therapeutics1.8+0.04+2.27%3.74PE
After Hours 1.82 +0.02 +1.11%
KLTOKlotho Neurosciences Inc0.41+0.1573+62.25%-- 
After Hours 0.38 -0.03 -7.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.